Genzyme's Gaucher disease drug hits main goals in 2 Phase III trials

02/18/2013 | Reuters · Fox Business

Eliglustat tartrate, an experimental drug from Sanofi unit Genzyme, met the primary goals of two late-stage trials involving patients with Gaucher disease. Eliglustat was associated with reductions in spleen size and matched Sanofi's Cerezyme in symptom response. The company plans to use the trials in seeking regulatory approval.

View Full Article in:

Reuters · Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health